These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12651705)

  • 1. Discoloration of parenteral ondansetron.
    H Tsui BC; Cave D
    Anesth Analg; 2003 Apr; 96(4):1239. PubMed ID: 12651705
    [No Abstract]   [Full Text] [Related]  

  • 2. Stability of ondansetron and dexamethasone infusion upon refrigeration.
    Rolin C; Hecq JD; Vanbeckbergen DF; Jamart J; Galanti LM
    Ann Pharmacother; 2011 Jan; 45(1):130-1. PubMed ID: 21156815
    [No Abstract]   [Full Text] [Related]  

  • 3. Stability of ondansetron hydrochloride in a total parenteral nutrient admixture.
    Kirkham JC; Rutherford ET; Cunningham GN; Daneshmand KA; Falls AL
    Am J Health Syst Pharm; 1995 Jul; 52(14):1557-8. PubMed ID: 7552902
    [No Abstract]   [Full Text] [Related]  

  • 4. Correction: chemical structures of serotonin and serotonin-receptor antagonists.
    Holder EP
    Ann Pharmacother; 1996 Sep; 30(9):1043. PubMed ID: 8876880
    [No Abstract]   [Full Text] [Related]  

  • 5. Ondansetron hydrochloride: a competitive serotonin 5-HT3 receptor blocker.
    Mohan KC; Ravikumar K
    Acta Crystallogr C; 1995 Dec; 51 ( Pt 12)():2627-9. PubMed ID: 8588861
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigation of colon-specific dosage forms of ondansetron prepared with natural polymers.
    Tuğcu-Demiröz F; Acartürk F; Takka S
    Pharmazie; 2006 Nov; 61(11):916-9. PubMed ID: 17152983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stability of ondansetron in large-volume parenteral solutions.
    Graham CL; Dukes GE; Kao CF; Bertch JM; Hak LJ
    Ann Pharmacother; 1992 Jun; 26(6):768-71. PubMed ID: 1535245
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug in adhesive type transdermal matrix systems of ondansetron hydrochloride: optimization of permeation pattern using response surface methodology.
    Swain K; Pattnaik S; Sahu SC; Patnaik KK; Mallick S
    J Drug Target; 2010 Feb; 18(2):106-14. PubMed ID: 19712026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stability of ondansetron hydrochloride injection in extemporaneously prepared oral solutions.
    Graham CL; Dukes GE; Fox JL; Kao CF; Hak LJ
    Am J Hosp Pharm; 1993 Jan; 50(1):106-8. PubMed ID: 8427264
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical development of ondansetron injection.
    Leak RE; Woodford JD
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 1():S67-9. PubMed ID: 2533902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of paclitaxel with ondansetron hydrochloride or ranitidine hydrochloride during simulated Y-site administration.
    Burm JP; Jhee SS; Chin A; Moon YS; Jeong E; Nii L; Fox JL; Gill MA
    Am J Hosp Pharm; 1994 May; 51(9):1201-4. PubMed ID: 7913797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nasal administration of ondansetron using a novel microspheres delivery system.
    Mahajan HS; Gattani SG
    Pharm Dev Technol; 2009; 14(2):226-32. PubMed ID: 19519195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ondansetron clinical pharmacokinetics.
    Roila F; Del Favero A
    Clin Pharmacokinet; 1995 Aug; 29(2):95-109. PubMed ID: 7586904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Compatibility of ondansetron hydrochloride and methylprednisolone sodium succinate in multilayer polyolefin containers.
    Bougouin C; Thelcide C; Crespin-Maillard F; Maillard C; Kinowski JM; Favier M
    Am J Health Syst Pharm; 2005 Oct; 62(19):2001-5. PubMed ID: 16174836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ondansetron and related 5-HT3 antagonists: recent advances.
    Oxford AW; Bell JA; Kilpatrick GJ; Ireland SJ; Tyers MB
    Prog Med Chem; 1992; 29():239-70. PubMed ID: 1475371
    [No Abstract]   [Full Text] [Related]  

  • 16. Selective separation and characterization of the stress degradation products of ondansetron hydrochloride by liquid chromatography with quadrupole time-of-flight mass spectrometry.
    Talluri MV; Keshari KK; Kalariya PD; Srinivas R
    J Sep Sci; 2015 May; 38(10):1625-32. PubMed ID: 25727389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Formulation and development of pH-independent/dependent sustained release matrix tablets of ondansetron HCl by a continuous twin-screw melt granulation process.
    Patil H; Tiwari RV; Upadhye SB; Vladyka RS; Repka MA
    Int J Pharm; 2015 Dec; 496(1):33-41. PubMed ID: 25863118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Determination of ondansetron and its hydroxy metabolites in human serum using solid-phase extraction and liquid chromatography/positive ion electrospray tandem mass spectrometry.
    Xu X; Bartlett MG; Stewart JT
    J Mass Spectrom; 2000 Nov; 35(11):1329-34. PubMed ID: 11114092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stability of ondansetron hydrochloride in syrups compounded from tablets.
    Williams CL; Sanders PL; Laizure SC; Stevens RC; Fox JL; Hak LJ
    Am J Hosp Pharm; 1994 Mar; 51(6):806-9. PubMed ID: 8010321
    [No Abstract]   [Full Text] [Related]  

  • 20. Ondansetron: design and development of oral pharmaceutical suspensions.
    Gallardo Lara V; Gallardo ML; Morales Hernandez ME; Ruiz Martinez MA
    Pharmazie; 2009 Feb; 64(2):90-3. PubMed ID: 19320280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.